Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn
The 8th CAR-TCR Summit is returning to Boston as the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug develope
Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, with more than 155,000 cases of NMSC reported in the UK every year.1,2 However, NMSC is significantly under-r
Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U
AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lea
Editor's Picks
